Images List Premium Download Classic

Atherosclerosis

Atherosclerosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Novel dgat2 inhibitors
Eli Lily And Company
June 14, 2018 - N°20180162825

The present invention provides compounds of the formula below: [formula should be inserted here] where a, x, r, and r2-r3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds.. .
Assessment of cardiac health and thrombotic risk in a patient
June 07, 2018 - N°20180153966

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity ...
Method of treating atherosclerosis in high triglyceride subjects
Novartis Ag
June 07, 2018 - N°20180153861

The present invention provides a compound of formula i for use in the treatment, amelioration and/or prevention of diseases and conditions associated with cetp activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein r1, x1, r7, r5, c, l and p are defined herein. The present invention further provides a combination of pharmacologically active ...
Atherosclerosis Patent Pack
Download + patent application PDFs
Atherosclerosis Patent Applications
Download + Atherosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Atherosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, ...
Virginia Commonwealth University
May 10, 2018 - N°20180127457

5-cholesten, 3β,25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
May 10, 2018 - N°20180125870

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity
The Methodist Hospital
May 03, 2018 - N°20180117176

Porous silicon (psi) microparticles (psm) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent psm-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies.
Atherosclerosis Patent Pack
Download + patent application PDFs
Atherosclerosis Patent Applications
Download + Atherosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Atherosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
April 19, 2018 - N°20180105518

The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (i): which are tropomyos-in-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth ...
Compounds for the prevention and treatment of cardiovascular diseases
Resverlogix Corp.
April 19, 2018 - N°20180104245

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein a-i (apoa-i), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.. .
Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
Mayo Foundation For Medical Education And Research
April 19, 2018 - N°20180104222

Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production.
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of ...
Volant Holdings Gmbh
April 12, 2018 - N°20180099001

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 ...
Ldl quantitation and methods of use
April 05, 2018 - N°20180092964

The present invention features, in certain aspects, methods of promoting endocytosis of ldl with α1pi or peptides derived from α1pi. The present invention also provides methods for decreasing ldl levels in response to α1pi augmentation therapy.
Compositions of protein receptor tyrosine kinase inhibitors
Purdue Pharma L.p.
March 29, 2018 - N°20180086777

The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, tropomysosin related kinases (trk), in particular the nerve growth factor (ngf) receptor, trka. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, ...
Pulsed introduction of low-dose rankl as a therapy for atherosclerosis
St. Louis University
March 29, 2018 - N°20180085431

Systems and methods for inhibiting atherosclerosis using foxp3+ cd8 t-cells (tcreg). Osteoclasts are induced to produce foxp3+ cd8 t-cells (tcreg) through introduction of a low-dose of a rank agonist suck as rankl.
Atherosclerosis Patent Pack
Download + patent application PDFs
Atherosclerosis Patent Applications
Download + Atherosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Atherosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods for treating cancer with trka receptor tyrosine kinase antagonists
March 22, 2018 - N°20180078545

The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.. .
Tricyclic analogues, preparation method and uses thereof
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
March 08, 2018 - N°20180064696

The present invention relates to a series of analogues of natural product pyripyropene a represented by general formula i and a preparation method and use thereof. More particularly, the present invention relates to analogues of the natural product pyripyropene a, a preparation method and use thereof as the acyl-coa:cholesterol acyltransferase 2 (acat2) inhibitors for the treatment of cardiovascular diseases such ...
Antibodies towards an extracellular region of nbcn1
Aarhus Universitet
March 01, 2018 - N°20180057588

The present application discloses antibodies or antigen binding fragment thereof specifically recognizing and binding an extracellular polypeptide region of human nbcn1. Experimental data are detailed for mouse nbcn1 antibodies.
Atherosclerosis imaging agents and methods of using the same
The General Hospital Corporation
March 01, 2018 - N°20180055953

Methods for detecting the presence of atherosclerotic structures in order to diagnose or prevent atherosclerosis are provided herein. In particular, it has been found that methylene blue injected intravenously acts as an excellent indicator because the compound targets high-risk plaque, atheroma, macrophages, and other atherosclerotic structures formed within the endothelial walls of a vessel of a subject.
Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
March 01, 2018 - N°20180055791

Activation of 5-ht2a receptors using agonists at surprisingly low concentrations was shown to potently inhibit tnf-α-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (r)-doi, even many hours after treatment with tnf-α.
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated ...
Vanderbilt University
February 22, 2018 - N°20180050083

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Compositions and methods for treating retinal degradation
University Of Kentucky Research Foundation
February 15, 2018 - N°20180044327

The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by alu rna associated with a cell, for reducing atp-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species ...
N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and ...
Pimco 2664 Limited
February 08, 2018 - N°20180037544

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction ...
Loading